Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation | |
---|---|---|
D029424 | Pulmonary Disease, Chronic Obstructive NIH | 0.38 |
D008173 | Lung Diseases, Obstructive NIH | 0.35 |
D006333 | Heart Failure NIH | 0.33 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
Leveraging a natural experiment approach, the investigators will examine rapidly changing telemedicine and in-person models of care during and after the COVID-19 crisis to determine whether certain patients could safely choose to continue telemedicine or telemedicine-supplemented care, rather than return to in-person care.
Description: Avoidable emergency department (ED) admissions will be obtained from claims data
Measure: Number of avoidable emergency department (ED) admissions Time: 30 days after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Avoidable emergency department (ED) admissions will be obtained from claims data
Measure: Number of avoidable emergency department (ED) admissions Time: 60 days after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Avoidable emergency department (ED) admissions will be obtained from claims data
Measure: Number of avoidable emergency department (ED) admissions Time: 6 months after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Avoidable emergency department (ED) admissions will be obtained from claims data
Measure: Number of avoidable emergency department (ED) admissions Time: 12 months after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Unplanned hospital admissions from the ED will be obtained from claims data
Measure: Number of unplanned hospital admissions from the ED Time: 30 days after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Unplanned hospital admissions from the ED will be obtained from claims data
Measure: Number of unplanned hospital admissions from the ED Time: 60 days after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Unplanned hospital admissions from the ED will be obtained from claims data
Measure: Number of unplanned hospital admissions from the ED Time: 6 months after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Unplanned hospital admissions from the ED will be obtained from claims data
Measure: Number of unplanned hospital admissions from the ED Time: 12 months the comparator arms of clinic-level telemedicine usedDescription: Continuity of care will be measured using the Bice-Boxerman Continuity of Care Index. The Bice-Boxerman continuity of care (COC) index reflects the relative share of all of a patient's visits during the year that are billed by distinct providers and/or practices. The index ranges from 0 to 1, where 0 indicates that each visit involved a different provider than all other visits, and 1 that all visits were billed by a single provider, representing continuity of care.
Measure: Continuity of care as assessed by the Bice-Boxerman Continuity of Care Index Time: 30 days after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Continuity of care will be measured using the Bice-Boxerman Continuity of Care Index. The Bice-Boxerman continuity of care (COC) index reflects the relative share of all of a patient's visits during the year that are billed by distinct providers and/or practices. The index ranges from 0 to 1, where 0 indicates that each visit involved a different provider than all other visits, and 1 that all visits were billed by a single provider, representing continuity of care.
Measure: Continuity of care as assessed by the Bice-Boxerman Continuity of Care Index Time: 60 days after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Continuity of care will be measured using the Bice-Boxerman Continuity of Care Index. The Bice-Boxerman continuity of care (COC) index reflects the relative share of all of a patient's visits during the year that are billed by distinct providers and/or practices. The index ranges from 0 to 1, where 0 indicates that each visit involved a different provider than all other visits, and 1 that all visits were billed by a single provider, representing continuity of care.
Measure: Continuity of care as assessed by the Bice-Boxerman Continuity of Care Index Time: 6 months after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Continuity of care will be measured using the Bice-Boxerman Continuity of Care Index. The Bice-Boxerman continuity of care (COC) index reflects the relative share of all of a patient's visits during the year that are billed by distinct providers and/or practices. The index ranges from 0 to 1, where 0 indicates that each visit involved a different provider than all other visits, and 1 that all visits were billed by a single provider, representing continuity of care.
Measure: Continuity of care as assessed by the Bice-Boxerman Continuity of Care Index Time: 12 months after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Continuity of care as assessed by the Breslau Usual Provider of Care measure. The Breslau Usual Provider of Care index is also an indicator of continuity of care, ranging from 0 to 1, where 1 represents continuity of care.
Measure: Continuity of care as assessed by the Breslau Usual Provider of Care measure Time: 30 days after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Continuity of care as assessed by the Breslau Usual Provider of Care measure. The Breslau Usual Provider of Care index is also an indicator of continuity of care, ranging from 0 to 1, where 1 represents continuity of care.
Measure: Continuity of care as assessed by the Breslau Usual Provider of Care measure Time: 60 days after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Continuity of care as assessed by the Breslau Usual Provider of Care measure. The Breslau Usual Provider of Care index is also an indicator of continuity of care, ranging from 0 to 1, where 1 represents continuity of care.
Measure: Continuity of care as assessed by the Breslau Usual Provider of Care measure Time: 6 months after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Continuity of care as assessed by the Breslau Usual Provider of Care measure. The Breslau Usual Provider of Care index is also an indicator of continuity of care, ranging from 0 to 1, where 1 represents continuity of care.
Measure: Continuity of care as assessed by the Breslau Usual Provider of Care measure Time: 12 months after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Continuity of care as assessed by attendance at follow-up appointment.
Measure: Continuity of care as assessed by attendance at follow-up appointment Time: 30 days after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Continuity of care as assessed by attendance at follow-up appointment.
Measure: Continuity of care as assessed by attendance at follow-up appointment Time: 60 days after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Continuity of care as assessed by attendance at follow-up appointment.
Measure: Continuity of care as assessed by attendance at follow-up appointment Time: 6 months after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Continuity of care as assessed by attendance at follow-up appointment.
Measure: Continuity of care as assessed by attendance at follow-up appointment Time: 12 months after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0059): Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%), which is the percentage of patients 18 - 75 years of age with diabetes who had hemoglobin A1c > 9.0% during the measurement period
Measure: Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0059): Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%) Time: 30 days after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0059): Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%), which is the percentage of patients 18 - 75 years of age with diabetes who had hemoglobin A1c > 9.0% during the measurement period
Measure: Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0059): Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%) Time: 60 days after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0059): Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%), which is the percentage of patients 18 - 75 years of age with diabetes who had hemoglobin A1c > 9.0% during the measurement period
Measure: Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0059): Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%) Time: 6 months after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0059): Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%), which is the percentage of patients 18 - 75 years of age with diabetes who had hemoglobin A1c > 9.0% during the measurement period
Measure: Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0059): Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%) Time: 12 months after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0018): Controlling High Blood Pressure, which is the percentage of patients 18 - 85 with hypertension diagnosis and adequate control (< 140/90 mmHg)
Measure: Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0018): Controlling High Blood Pressure Time: 30 days after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0018): Controlling High Blood Pressure, which is the percentage of patients 18 - 85 with hypertension diagnosis and adequate control (< 140/90 mmHg)
Measure: Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0018): Controlling High Blood Pressure Time: 60 days after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0018): Controlling High Blood Pressure, which is the percentage of patients 18 - 85 with hypertension diagnosis and adequate control (< 140/90 mmHg)
Measure: Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0018): Controlling High Blood Pressure Time: 6 months after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0018): Controlling High Blood Pressure, which is the percentage of patients 18 - 85 with hypertension diagnosis and adequate control (< 140/90 mmHg)
Measure: Evidence of controlled disease as indicated by as indicated by the National Quality Forum (NQF 0018): Controlling High Blood Pressure Time: 12 months after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Days per month not in hospital or institutional setting
Measure: Days at home Time: 30 days after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Days per month not in hospital or institutional setting
Measure: Days at home Time: 60 days after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Days per month not in hospital or institutional setting
Measure: Days at home Time: 6 months after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Days per month not in hospital or institutional setting
Measure: Days at home Time: 12 months after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: Patient experiences based on the Patient Satisfaction Questionnaire (PSQ-18), which is a 5-scale questionnaire including questions on patient satisfaction, communication quality with providers and accessibility/convenience of care.
Measure: Patient experiences based on the Patient Satisfaction Questionnaire (PSQ-18) Time: 12 months after the exposure to one of the comparator arms of clinic-level telemedicine usedDescription: For individuals who accessed a telemedicine visit, we will ask questions based on the validated Telehealth Usability Questionnaire (TUQ), including the ease of use and access to the telemedicine service, quality of the interaction with the provider, and satisfaction
Measure: Ease of use and access to telemedicine based on Telehealth Usability Questionnaire (TUQ) Time: 12 months after the exposure to one of the comparator arms of clinic-level telemedicine usedAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports